SCHEMBL2058088

SCHEMBL2058088

CCCN(CCC)S(C)(=O)=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.63
CA12 O43570 5/20 0.57
CA2 P00918 2/20 0.57
CA14 Q9ULX7 2/20 0.57
PER2 O15055 4/20 0.38
CA9 Q16790 3/20 0.36
CA7 P43166 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
ABCC2 Q92887 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
UGT1A7 Q9HAW7 1/20 0.36
SLC22A11 Q9NSA0 1/20 0.36
KDM4E B2RXH2 2/20 0.36
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312297 0.89 CA1 (0.52) CA1CA12CA2CA14PER2
SCHEMBL13693145 0.88 CA1 (0.57) CA1CA12CA2CA14PER2
SCHEMBL16261608 0.87 CA1 (0.50) CA1CA12CA2CA14PER2
SCHEMBL31399257 0.87 CA1 (0.52) CA1CA12CA2CA14PER2
SCHEMBL16015725 0.84 CA1 (0.52) CA1CA12CA2CA14PER2
SCHEMBL8654027 0.82 CA1 (0.43) CA1CA12CA2CA14CA9
SCHEMBL17348037 0.82 CA1 (0.44) CA1CA12CA2CA14PER2
SCHEMBL24726809 0.78 CA1 (0.41) CA1CA12CA2CA14PER2
SCHEMBL2127290 0.78 DNM1 (0.46) CA1CA12CA2CA9TSHR
SCHEMBL12669289 0.78 DNM1 (0.46) CA1CA12CA2CA9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103911615-B Etching agent composite for copper-containing metal 东友精细化工有限公司 2017-08-22 CN claimed
US-20230257357-A1 PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE BACAINN BIOTHERAPEUTICS, LTD. (KY) 2023-08-17 US disclosed
US-20230250063-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-08-10 US disclosed
WO-2022011083-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2022-01-13 WO disclosed
CN-103911615-B Etching agent composite for copper-containing metal 东友精细化工有限公司 2017-08-22 CN disclosed
US-20160313639-A1 PHOTOSENSITIVE RESIN COMPOSITION, PIXEL LAYER, PROTECTIVE FILM, SPACER, THIN-FILM TRANSISTOR, COLOR FILTER, AND LIQUID CRYSTAL DISPLAY APPARATUS CHI MEI CORPORATION (TW) 2016-10-27 US disclosed
US-9274419-B2 Blue photosensitive resin composition for color filter and application thereof CHI MEI CORPORATION (TW) 2016-03-01 US disclosed
US-20150268554-A1 BLUE PHOTOSENSITIVE RESIN COMPOSITION FOR COLOR FILTER AND APPLICATION THEREOF CHI MEI CORPORATION (TW) 2015-09-24 US disclosed
US-20150260889-A1 NEAR-INFRARED CUT FILTER ASAHI GLASS COMPANY, LIMITED (JP) 2015-09-17 US disclosed
US-9086532-B2 Blue photosensitive resin composition for color filter and uses thereof CHI MEI CORPORATION (TW) 2015-07-21 US disclosed
US-20110229771-A1 NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2011-09-22 US disclosed
US-7981553-B2 Nonaqueous electrolyte and lithium secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2011-07-19 US disclosed
US-20110159380-A1 NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2011-06-30 US disclosed
US-20100227226-A1 NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2010-09-09 US disclosed
US-20100021823-A1 NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2010-01-28 US disclosed
US-7575833-B2 Nonaqueous electrolyte and lithium secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2009-08-18 US disclosed
US-20070238025-A1 NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2007-10-11 US disclosed
US-7223502-B2 Nonaqueous electrolyte and lithium secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2007-05-29 US disclosed
US-20050118512-A1 Nonaqueous electrolyte and lithium secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2005-06-02 US disclosed
WO-2004043953-A1 PYRIMIDINE COMPOUNDS CYCLACEL LIMITED (GB) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257357-A1 PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE NLRP3, PYCARD, NLRP1 CA1 3887/4885CA12 3513/4885CA2 3362/4885
US-20230250063-A1 PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS FPR2, FPR1, FPR3 CA1 4688/4885CA12 4610/4885CA2 3805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.